Caplin Point Laboratories Limited (CAPLIPOINT) Price & Analysis

Compare

4 Followers

CAPLIPOINT Stock Chart & Stats

₹1845.95

-₹76.70(-2.97%)

At close: Jan 09 4:00 PM EST

₹1845.95

-₹76.70(-2.97%)

Day’s Range― - ―

52-Week Range₹1,551.05 - ₹2,396.95

Previous CloseN/A

Volume128.91K

Average Volume (3M)3.75K

Market Cap

₹130.93B

Enterprise Value₹123.71B

Total Cash (Recent Filing)₹9.03B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)21.3

Beta1.45

Next Earnings

May 14, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.31%

Share Statistics

EPS (TTM)21.80

Shares Outstanding76,011,696

10 Day Avg. Volume2,866

30 Day Avg. Volume3,752

Financial Highlights & Ratios

PEG Ratio1.63

Price to Book (P/B)5.30

Price to Sales (P/S)7.78

P/FCF Ratio62.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue & Margin StrengthCaplin Point shows multi-year revenue expansion combined with robust gross and operating margins, indicating durable cost control and pricing power in its product mix. Sustained margin breadth supports reinvestment in manufacturing and steady free cash flow conversion over medium term.

Healthy Balance Sheet (low Leverage)A low leverage profile and a high equity ratio provide financial flexibility for capex, regulatory filings, and selective M&A without stressing cash flow. Strong ROE trends indicate capital is being deployed profitably, reducing refinancing and solvency risks over the next several quarters.

Differentiated Dosage Focus & Regulatory ReachSpecialization in injectables and ophthalmics creates structural product differentiation versus commoditized generics, supporting stronger pricing and customer stickiness. Coupled with demonstrated ability to secure approvals across markets, this supports sustainable overseas revenue streams and higher margin durability.

Bears Say

Tender-driven Sales ExposureSignificant exposure to tender-based and institutional procurement introduces revenue cyclicality and pricing pressure. Competitive bid processes can sharply compress margins in certain geographies, reducing predictability of medium-term cash flows and requiring continuous scale or cost advantages to defend profitability.

Regulatory & Geographic ComplexityServing many regulated and semi-regulated markets raises compliance, registration upkeep, and country-specific regulatory risk. Maintaining dossiers and approvals is resource intensive and can delay launches or shipments, creating multi-month lags between investment and revenue realization across markets.

Execution Risk From Specialized ManufacturingConcentration in complex dosage forms demands high-quality manufacturing, strict regulatory compliance and ongoing capex. Any plant downtime, quality failure, or inspection issue can disproportionately disrupt supply and revenues, making operational execution a persistent medium-term risk.

Caplin Point Laboratories Limited News

Caplin Point Buys $473 Million Portfolio of US-Approved Injectable and Ophthalmic ANDAs

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) has shared an update. Caplin Point Laboratories, through its subsidiaries Caplin...

2M ago

Caplin Steriles Secures USFDA Approval for Acetaminophen Injection

The latest update is out from Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ). Caplin Steriles Limited, a subsidiary...

2M ago

Caplin Point Laboratories Announces Financial Results and New Appointments

An announcement from Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) is now available. Caplin Point Laboratories Limited announced...

4M ago

Caplin Point Laboratories Announces Trading Window Closure

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) just unveiled an announcement. Caplin Point Laboratories Limited announced the closure...

5M ago

Caplin Point Laboratories Sets Record Date for Dividend Ahead of AGM

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) has provided an announcement. Caplin Point Laboratories Limited has announced the...

7M ago

Caplin Point Laboratories Limited (CAPLIPOINT) Declares Q2 Dividend: Important Details for Shareholders

Caplin Point Laboratories Limited (NSE: CAPLIPOINT) has declared, under its dividend policy, a yearly cash dividend in the...

9M ago

CAPLIPOINT FAQ

What was Caplin Point Laboratories Limited’s price range in the past 12 months?

Caplin Point Laboratories Limited lowest stock price was ₹1551.05 and its highest was ₹2396.95 in the past 12 months.

What is Caplin Point Laboratories Limited’s market cap?

Caplin Point Laboratories Limited’s market cap is ₹130.93B.

When is Caplin Point Laboratories Limited’s upcoming earnings report date?

Caplin Point Laboratories Limited’s upcoming earnings report date is May 14, 2026 which is in 84 days.

How were Caplin Point Laboratories Limited’s earnings last quarter?

Caplin Point Laboratories Limited released its earnings results on Feb 05, 2026. The company reported ₹21.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹21.8.

Is Caplin Point Laboratories Limited overvalued?

According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Caplin Point Laboratories Limited pay dividends?

Caplin Point Laboratories Limited pays a Quarterly dividend of ₹3 which represents an annual dividend yield of 0.31%. See more information on Caplin Point Laboratories Limited dividends here

What is Caplin Point Laboratories Limited’s EPS estimate?

Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Caplin Point Laboratories Limited have?

Caplin Point Laboratories Limited has 76,011,696 shares outstanding.

What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?

Caplin Point Laboratories Limited reported an EPS of ₹21.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.419%.

Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?

Currently, no hedge funds are holding shares in IN:CAPLIPOINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.